Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
Alicia T. Widge, Nadine Rouphael, Lisa A. Jackson, Evan J. Anderson, Paul C. Roberts, Mamodikoe Makhene, James D. Chappell, Mark R. Denison, Laura J. Stevens, Andrea J. Pruijssers, Adrian B. McDermott, Britta Flach, Bob C. Lin, Nicole A. Doria‐Rose, Sijy O’Dell, Stephen D. Schmidt, Kathleen M. Neuzil, Hamilton Bennett, Brett Leav, Mat Makowski, Jim Albert, Kaitlyn Cross, Venkata Viswanadh Edara, Katharine Floyd, Mehul S. Suthar, Wendy Buchanan, Catherine J. Luke, Julie E. Ledgerwood, John R. Mascola, Barney S. Graham, John H. Beigel
Abstract
Immunogenicity and the mRNA-1273 SARS-CoV-2 Vaccine Thirty-four adults received two 100-μg injections of the mRNA-1273 SARS-CoV-2 vaccine, and serum anti–spike protein and neutralizing antibody tit...
Topics & Concepts
ImmunogenicityMessenger RNASevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyVaccinationAntibodyNeutralizing antibodyCoronavirus disease 2019 (COVID-19)Medicine2019-20 coronavirus outbreakSpike ProteinImmunologyBiologyOutbreakGeneInternal medicineGeneticsDiseaseInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesImmunotherapy and Immune Responses